The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Living in a disadvantaged neighborhood contributes to a rare form of heart failure known as peripartum cardiomyopathy, a ...

Affecting 1 in 500 people, hypertrophic cardiomyopathy is a condition in which the walls of the left ventricle, the heart's ...

Alnylam Pharmaceuticals has landed a long-awaited FDA decision that expands use of its drug, Amvuttra, to the treatment of a type of cardiomyopathy that’s growing in prevalence. It’s the ...

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...

American Heart Month may be over, but experts still want to bring awareness to a condition that many people may have without ...

Sirolimus, the active ingredient in Felycin-CA1, at a higher dose is used as an immunosuppressant in human patients receiving ...

Background Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience worsening cardiac disease (WCD) ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...